KG004

KG004 is a trispecific antibody under development by Kaigene for the treatment of autoimmune disorders. The drug is currently in preclinical or early clinical development, with its highest reported R&D status being Phase 0 for unspecified autoimmune diseases. The precise mechanism of action has not been disclosed, and no novel mechanism has been claimed. As a trispecific antibody, KG004 is designed to simultaneously target three different antigens or epitopes, which may allow for more effective modulation of immune responses compared to monospecific or bispecific antibodies. No adverse events have been reported at this stage, and there are no approved indications or FDA designations associated with the drug[2][1].